

Licence comparisons and costs for formulary DPP-4 inhibitors (Gliptins)

Drug	Strengths	Doses (maximal or usual)	28 day cost	Mono-therapy	Dual Therapy			Triple Therapy		Addition to Insulin	Renal Impairment	Hepatic impairment
					metformin	sulfonylurea	pioglitazone	metformin sulfonylurea	metformin pioglitazone			
Alogliptin	6.25mg 12.5mg 25mg	25mg ONCE daily	£26.60	No	Yes	Yes	Yes	Limited data	Yes	Yes +/- metformin only	Moderate (≥ 30 to ≤ 50 mL/min) 12.5mg once daily. Severe (< 30 mL/min) to ESRD 6.25mg once daily.	Mild to moderate no dose adjustment necessary. Severe: no data. Not recommended.
Sitagliptin	25mg 50mg 100mg	100mg ONCE Daily	£33.26	Yes	Yes	Yes	Yes	Yes	Yes	Yes +/- metformin only	Moderate (≥ 30 to ≤ 50 mls/min): 50mg once daily. Severe (< 30 mls/min) to ESRD 25mg once daily.	Mild to moderate: no dose adjustment necessary. Severe: no data. Use cautiously.
Linagliptin	5mg	5mg ONCE daily	£33.26	Yes	Yes	No	No	Yes	No	Yes +/- metformin only	No dosage adjustment.	No dose reduction but limited experience.
Saxagliptin	2.5mg 5mg	5mg ONCE daily	£31.60	Yes	Yes	Yes	Yes	Yes	No	Yes +/- metformin only	Moderate to severe (>15 to <60 mls/min) 2.5mg once daily ESRD Not recommended.	Mild to moderate: no dose adjustment necessary. Use cautiously. Severe: not recommended

No dosage adjustment is recommended in elderly solely based on age; however caution is needed in this population. Refer to the SmPCs for complete information.

Comparative data table produced by PrescQIPP September 2014 and adapted by the Medicines Management Team, Cambridgeshire and Peterborough CCG December 2014. Version 1.0

References

Alogliptin. PrescQIPP September 2014. Available at <http://www.prescqipp.info/newsfeed/bulletin-78-launched-alogliptin>
 Summary of Product Characteristics. Januvia (sitagliptin), Merck Sharp & Dohme. Last updated 6th November 2014. Accessed 02/12/14 via <https://www.medicines.org.uk/emc/medicine/19609>
 Summary of Product Characteristics. Galvus (viladagliptin), Novartis Pharmaceuticals Ltd. Last updated 26th June 2014. Accessed 02/12/14 via <https://www.medicines.org.uk/emc/medicine/20734>
 Summary of Product Characteristics. Trajenta (Linagliptin), Boehringer Ingelheim Ltd. Last updated 29th October 2014. Accessed 02/12/14 via <https://www.medicines.org.uk/emc/medicine/25000>
 Summary of Product Characteristics. Onglyza (saxagliptin), AstraZeneca UK. Last updated 27th October 2014. Accessed 02/12/14 via <https://www.medicines.org.uk/emc/medicine/22315>
 Summary of Product Characteristics. Vipidia (alogliptin), Takeda Pharmaceuticals Ltd. Last updated 11th November 2014. Accessed 02/12/14 via <https://www.medicines.org.uk/emc/medicine/28513>